key: cord-1032597-idgl1hrb authors: Nagamine, Todd; Randhawa, Sandeep; Nishimura, Yoshito; Huang, Ricky; Leesutipornchai, Thiratest; Benavente, Kevin; Yoshimura, Stephanie; Zhang, James; Kanitsorphan, Chanavuth title: Characteristics of bradyarrhythmia in patients with COVID‐19: Systematic scoping review date: 2022-03-03 journal: Pacing Clin Electrophysiol DOI: 10.1111/pace.14466 sha: 0b62fe2cab9c7cf8c12e87146df08fd0f2340f55 doc_id: 1032597 cord_uid: idgl1hrb COVID‐19 has recently been associated with the development of bradyarrhythmias, although its mechanism is still unclear. We aim to summarize the existing evidence regarding bradyarrhythmia in COVID‐19 and provide future directions for research. Following the PRISMA Extension for Scoping Reviews, we searched MEDLINE and EMBASE for all peer‐reviewed articles using keywords including“Bradycardia,” “atrioventricular block,” and “COVID‐19″ from their inception to October 13, 2021. Forty‐three articles, including 11 observational studies and 59 cases from case reports and series, were included in the systematic review. Although some observational studies reported increased mortality in those with bradyarrhythmia and COVID‐19, the lack of comparative groups and small sample sizes hinder the ability to draw definitive conclusions. Among 59 COVID‐19 patients with bradycardia from case reports and series, bradycardia most often occurred in those with severe or critical COVID‐19, and complete heart block occurred in the majority of cases despite preserved LVEF (55.9%). Pacemaker insertion was required in 76.3% of the patients, most of which were permanent implants (45.8%). This systematic review summarizes the current evidence and characteristics of bradyarrhythmia in patients with COVID‐19. Further studies are critical to assess the reversibility of bradyarrhythmia in COVID‐19 patients and to clarify potential therapeutic targets including the need for permanent pacing. thought that cardiac involvement, especially in the case of bradycardia in SARS-CoV2, involves direct infiltration of the myocardial cells aggravating preexisting conduction disease, resulting in bradyarrhythmia. 6 This is supported by the fact that SARS-CoV2 has been shown to activate angiotensin converting enzyme 2 (ACE2) receptors, known to be present in sinoatrial nodal cells. 7 Another area of consideration is cardiac damage as a secondary manifestation. A suggested mechanism for cardiac damage is secondary to hypoxemia due to COVID- 19 , which can also aggravate pre-existing arrhythmic conditions. 6 Similarly, cytokine storm, triggered by an imbalance in the response of types 1 and 2 helper cells, has also been linked to cardiac myocyte injury which could indiscriminately aggravate cardiovascular diseases. 8 There has been a large area of focus related to cardiac injury as authors have attempted to establish a correlation with severity of illness, mortality, and long-term prognostication, with little emphasis specifically on bradyarrhythmia. 6 In this systemic scoping review, we aimed to analyze bradyarrhythmia in COVID-19 patients to further characterize this specific cardiac manifestation better to help suggest future studies and ideas for management and therapy. This is a systematic scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews (PRISMA-ScR). [9] [10] See Appendix S1 for PRISMA-ScR Checklist of the present study. We searched MEDLINE and EMBASE for all peer-reviewed articles from inception to October 13th, 2021. No filters for study design and language were used. A manual screening for additional pertinent articles was done using the reference lists of all articles that met the eligibility criteria. The search strategy involved relevant keywords, including "Bradycardia," "AV block," "atrioventricular block," and "COVID-19." The search was conducted by two authors (TN and YN) independently. See Appendix S2 for detailed search terms. The criteria for the inclusion of articles are the following: A standardized data collection form that followed the PRISMA and In this scoping review, we identified 11 observational studies that included patients with bradyarrhythmia and COVID-19 and 59 patients with bradyarrhythmia in COVID-19 from case reports and series. Our results showed that patients with severe or critical COVID-19 may be more likely to have bradyarrhythmia, although there are no observational studies with comparative groups that exclusively looked into bradycardia in COVID-19 to date. Interestingly, more than half of the patients included in our studies had complete AVB requiring either permanent and/or temporary pacemakers, with most of whom had preserved LVEF. Further prospective studies are warranted to assess the need for permanent pacing in these patients. Bradycardia has been reported as a potential rare complication of SARS-CoV infection, although its mechanism is unclear. 53 Several limitations in this study should be noted. First, due to the time constraints, we were unable to contact authors to obtain data not mentioned in the literature, leading to reporting bias. Second, we included only peer-reviewed articles in the systematic review, excluding conference abstracts or preprints, which may cause selection bias. In addition, cases with transient nonsevere bradycardia in COVID-19 patients might not have been reported, which could lead to publication bias. However, this is the first systematic review to investigate the characteristics of bradyarrhythmia in COVID-19 patients. The data presented may be used by frontline clinicians to determine treatment planning for similar patients, including in decisions whether to proceed with a permanent or temporary pacemaker. In conclusion, this systematic review summarizes the current body of evidence and characteristics of bradyarrhythmia in patients with COVID-19. While it remains hypothetical, pathophysiology may be multifactorial with potential direct myocardial injury, iatrogenicity of medications, cytokine-related effects, and/or hypoxia as contributing factors. Further studies are critical to assess the reversibility of bradyarrhythmia in COVID-19 patients as well as to clarify potential therapeutic targets, including HIF or pro-inflammatory cytokines. The authors declare no conflicts of interest in association with the present study. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies Cardiovascular manifestations in severe and critical patients with COVID-19 Electrocardiographic manifestations of COVID-19 Atrioventricular and Sinus Node Dysfunction in Stable Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia Cardiac and arrhythmic complications in patients with COVID-19 The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Reporting scoping reviews-PRISMA ScR extension PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation Sinus bradycardia: an unusual manifestation of mild to moderate COVID-19 pneumonia Association between electrocardiographic features and mortality in COVID-19 patients Remdesivir-induced bradycardia in COVID-19: a single center prospective study Bradyarrhythmias in patients with COVID-19: marker of poor prognosis? Atrial Arrhythmias in Patients with Severe COVID-19 Cardiovascular complications and its impact on outcomes in COVID-19 Cardiac arrhythmias amongst hospitalised Coronavirus 2019 (COVID-19) patients: Prevalence, characterisation, and clinical algorithm to classify arrhythmic risk Epidemiological, demographic, laboratory, clinical management, and outcome data of symptomatic bradyarrhythmia in COVID-19 patients Electrocardiogram analysis of patients with different types of COVID-19 The prognostic significance of electrocardiography findings in patients with coronavirus disease 2019: A retrospective study Remdesivir therapy causing bradycardia in COVID-19 patients: two case reports Paroxysmal atrioventricular block in a relatively young patient with covid-19 Prevalence of bradyarrhythmias needing pacing in COVID-19 Atypical presentation of COVID-19 as subclinical myocarditis with persistent high-degree atrioventricular block treated with pacemaker implant Novel behavior of the 2019 Novel Coronavirus with invasion of the cardiac conduction system in the young severe sinus bradycardia: an unusual cardiac manifestation of COVID-19 Symptomatic sinus bradycardia due to electrolyte imbalances in syndrome of inappropriate antidiuretic hormone (SIADH) related covid-19: a case report Symptomatic Bradycardia in Covid-19 hospitalized patients: a case series Case report: high-grade atrioventricular block in suspected COVID-19 myocarditis Reversible complete heart block in a patient with coronavirus disease 2019 A case report of unusually long episodes of asystole in a severe COVID-19 patient treated with a leadless pacemaker Unusual cardiac presentation of COVID-19 with significant sinus pauses High-degree atrioventricular block in COVID-19 hospitalized patients SARS-CoV-2 detection and sequencing in heart tissue associated with myocarditis and persistent arrhythmia: A case report Heart block in patients with coronavirus disease 2019: a case series of 3 patients infected with SARS-CoV-2 Complete heart block and itchy rash in a patient with COVID-19 Bradyarrhythmias in patients with COVID-19: a case series Poudel Chandra Mani. A Patient Infected with SARS-CoV-2 Presenting with A case of complete heart block in a COVID-19 infected patient Characteristic electrocardiographic manifestations in patients with COVID-19 Persistent complete heart block in a patient with COVID-19 infection: a case report Pacemaker implantation in a COVID-19 patient. Balancing the patient's needs and the team's risk of exposure Suspected hydroxychloroquine-induced sinus bradycardia and qtc prolongation in a patient with COVID-19 Heart Brake: an unusual cardiac manifestation of COVID-19 A case report of a rare cardiac complication in novel coronavirus disease An unusual presentation of cardiac involvement during the COVID-19 pandemic Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series Management of Pacemaker Implantation during COVID-19 Infection COVID-19 "Fulminant Myocarditis" successfully treated with temporary mechanical circulatory support Complete heart block associated with Remdesivir in COVID-19: a case report Complete heart block in patients infected with SARS-CoV-2: A case series from a developing country Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome Cardiovascular complications of severe acute respiratory syndrome Bradyarrhythmias in patients with SARS-CoV-2 infection: A narrative review and a clinical report COVID-19 infection and cardiac arrhythmias Cardiac arrhythmias in patients with COVID-19 Cardiovascular adaptation to hypoxia and the role of peripheral resistance Mechanisms mediating the heart rate response to hypoxemia Hypoxia-inducible factors and obstructive sleep apnea Hypoxia-inducible factor 1 and cardiovascular disease Hypoxia-inducible factors in physiology and medicine Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19) Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cellderived cardiomyocytes Characteristics of bradyarrhythmia in patients with COVID-19: systematic scoping review